**FOI Ref: 6480**

**Category(ies): Clinical - Service Activity**

**Subject: Radium- 223 Molecular Radiotherapy Use**

**Date Received: 06/07/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| **Question 1**Please complete the table below:

|  |  |
| --- | --- |
| Radium-223 dichloride service |   |
| Is radium-223 dichloride offered in your trust as a treatment for prostate cancer? (y/n) | No - Patients are diagnosed at The Rotherham NHS Foundation Trust but are referred for Treatment to a Cancer Centre such as Sheffield Teaching Hospitals (STH). Please redirect your request to Sheffield Teaching Hospitals, the email address for STH is foi@sth.nhs.uk |
| If yes, please list the indications for which it is used in your trust? |   |

  |
| **Question 2**Please detail the number of patients that are treated with radium-223 dichloride in your trust:

|  |  |
| --- | --- |
| Patient numbers |   |
| Number of prostate cancer patients completing treatment with radium-223 dichloride per year |   |
| Number of prostate cancer patients initiating radium-223 dichloride treatment per year |   |
| What is the average number of cycles administered per patient in your service? |   |
| What is the waiting time before patients can receive radium-223 dichloride? |   |
| How many patients are initiated with cabazitaxel per year in your trust? |   |

  |
| **Question 3**In what department is molecular radiotherapy provided in your trust?

|  |  |  |
| --- | --- | --- |
| Administration | Radium-223 dichloride | 177Lutetium based radioligand therapy for neuroendocrine tumours |
| Nuclear Medicine |   |   |
| Medical Physics |   |   |
| Radiotherapy |   |   |
| Oncology |   |   |
| Urology |   |   |
| Other |   |   |
| N/A |   |   |

  |
| **Question 4**What codes are associated with molecular radiotherapy administration in your trust?

|  |  |  |
| --- | --- | --- |
| NHS codes | HRG | OPCS code |
| Radium-223 dichloride |   |   |

  |
| **Question 5**Please complete the table below:

|  |  |  |
| --- | --- | --- |
| Who performs the administration of the treatment? | Radium-223 dichloride | 177Lutetium based radioligand therapy for neuroendocrine tumours |
| CNS |   |   |
| Technician |   |   |
| NM nurse |   |   |
| NM physicist |   |   |
| NM Consultant |   |   |
| Oncologist |   |   |
| Other *(please state)* |   |   |

 |
| **Question 6**Who holds the ARSAC licence in your trust?

|  |  |  |  |
| --- | --- | --- | --- |
| Administration | (y/n) | Radium-223 dichloride | 177Lutetium based radioligand therapy for neuroendocrine tumours |
| Nuclear Medicine consultant |   |   |   |
| Clinical Oncologist |   |   |   |
| Radiologist |   |   |   |
| Other *(please state speciality)* |   |   |   |

  |
| **Question 7**Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your trust or are they outsourced?

|  |  |  |
| --- | --- | --- |
| Radiation safety (y/n) | Conducted in-house *(If so, please provide the number of full-time equivalents providing these services in your centre)* | Outsourced |
| Radioactive Waste Adviser (RWA) |   |   |
| Radiation Protection Adviser (RPA) |   |   |
| Medical Physics Expert (MPE) |   |   |

  |
| **Question 8**Please complete the table below:

|  |  |  |  |
| --- | --- | --- | --- |
| Dosimetry  | (y/n) | If yes, what is the schedule after each administration? | If yes, is this analysed in-house or outsourced? |
| Is dosimetry performed for radium-223 dichloride prostate cancer patients? |   |   |   |

 |